BRIEF-AstraZeneca CEO says MYSTIC cancer drug trial "not binary"

Feb 2 Astrazeneca CEO Pascal Soriot told reporters after Q4 results:
* Believes in strong science-led FDA
* FDA has already taken steps to accelerate approvals, especially in cancer
* Limit to how fast FDA can go, in response to Trump comments on faster approvals
* U.S. price pressures will continue
* Primary care drugs a particular focus for U.S. pricing pressure
* Will adjust to U.S. price pressures as have done for long time in Europe
* MYSTIC study "not binary
* "Very unlikely" that neither mono or combination work in MYSTIC


* CAn look at bristol filing decision on chemo-I/O combo as positive or negative for AZ
* Believes UK government is very committed to creating strong life sciences industry post-Brexit
* Logical to assume UK will have to have its own drugs regulator post-brexit but may have reciprocal approval agreement with EMA Further company coverage: (Reporting by UK bureau)